

ARCHIVES OF GENERAL PSYCHIATRY

HOME

HELP

[Ray Gonzalez](#) | [Change Password](#) | [E-mail Alerts](#) | [File Drawer](#) | [Sign Out](#)

Vol. 61 No. 9, September 2004

Original Article

[TABLE OF CONTENTS >](#)**Featured Link**

- [E-mail Alerts](#)

Article Options

- [Abstract](#)
- [PDF](#)
- [Send to a Friend](#)
- [Readers Reply](#)
 - [Submit a reply](#)
- [Related article](#)
- [Similar articles in this journal](#)

Literature Track

- [Add to File Drawer](#)
- [Download to Citation Manager](#)
- [PubMed citation](#)
- [Articles in PubMed by](#)
 - [Hogarty GE](#)
 - [Zoretich R](#)
- [Articles that cite this article](#)
- [ISI Web of Science \(23\)](#)
- [Contact me when this article is cited](#)

Topic Collections

- [Randomized Controlled Trial](#)
- [Cognitive Therapy](#)
- [Schizophrenia](#)
- [Topic Collection Alerts](#)

Cognitive Enhancement Therapy for Schizophrenia

Effects of a 2-Year Randomized Trial on Cognition and Behavior

Gerard E. Hogarty, MSW; Samuel Flesher, PhD; Richard Ulrich, MS; Mary Carter, PhD; Deborah Greenwald, PhD; Michael Pogue-Geile, PhD; Matcheri Kechavan, MD; Susan Cooley, MSN; Ann Louise DiBarry, MSN; Ann Garrett, PhD; Haranath Parepally, MD; Rebecca Zoretich, MSEd

Arch Gen Psychiatry. 2004;61:866-876.

ABSTRACT

Background Deficits in social cognition and neurocognition are believed to underlie schizophrenia disability. Attempts at rehabilitation have had circumscribed effects on cognition, without concurrent improvement in broad aspects of behavior and adjustment.

Objective To determine the differential effects of cognitive enhancement therapy (a recovery-phase intervention) on cognition and behavior compared with state-of-the-art enriched supportive therapy.

Design A 2-year, randomized controlled trial with neuropsychological and behavioral assessments completed at baseline and at 12 and 24 months.

Setting An outpatient research clinic housed in a medical center's comprehensive care service for patients with severe mental illness.

Patients A total of 121 symptomatically stable, non-substance-abusing but cognitively disabled and chronically ill patients with schizophrenia or schizoaffective disorder.

Interventions Cognitive enhancement therapy is a multidimensional, developmental approach that integrates computer-assisted training in neurocognition with social cognitive group exercises. Enriched supportive therapy fosters illness management through applied coping strategies and education.

Main Outcome Measures Six highly reliable summary measures—Processing Speed, Neurocognition, Cognitive Style, Social Cognition, Social Adjustment and Symptoms—were tested using analysis of covariance and linear trend analysis.

Results At 12 months, robust cognitive enhancement therapy effects were observed on the Neurocognition and Processing Speed composites ($P < .003$), with marginal effects observed on the behavioral composites. By 24 months, differential cognitive enhancement therapy effects were again observed for the 2 neuropsychological composites and for Cognitive Style ($P = .001$), Social Cognition ($P = .001$), and Social Adjustment ($P = .01$). As expected, no differences were observed on the residual Symptoms composite. Effects were unrelated to the type of antipsychotic medication received. Enriched

supportive therapy also demonstrated statistically significant within-group effect sizes, suggesting that supportive psychotherapy can also have positive, although more modest, effects on cognitive deficits.

Conclusion Many cognitive deficits and related behaviors of patients with stable schizophrenia are improved when sufficient exposure to relevant rehabilitation is provided.

INTRODUCTION

Schizophrenia is a leading cause of disability throughout the world.¹ Numerous, but often cross-sectional, studies have now shown correlations between neurocognitive deficits and behavior.² Concurrent impairment in social cognition has also been proposed as an important rate-limiting factor to recovery.³⁻⁶ These observations have stimulated various neurocognitive rehabilitation approaches.⁷⁻¹⁸ Sample sizes have been small (30-90 individuals), and many have included severely impaired, hospitalized patients. Treatment exposure has been limited (median, approximately 4 months), and no trial has exceeded 9 months. Successful attempts to improve neuropsychological (NP) test performance have been reported,¹⁹⁻²¹ as has some evidence of generalization to untrained NP tests.^{12, 16, 22-23} However, concurrent effects on broad aspects of functioning and behavior have been viewed as small and lacking generalization.^{15, 18}

Cognitive enhancement therapy (CET) was developed and piloted in the early to middle 1990s as an integrated approach to the enhancement of neurocognitive and social cognitive abilities. It attempts to capitalize on a presumed neuroplasticity reserve believed to respond to enriched cognitive experiences.²⁴ Cognitive enhancement therapy is a recovery-phase intervention for symptomatically stable schizophrenic outpatients with reduced relapse risk (who nevertheless remain socially and cognitively disabled), an increasing population in the modern era of atypical antipsychotic medications.²⁵ A 2-year, randomized study was undertaken between January 1995 and February 2002, together with a 1-year follow-up. This article describes the results of the 2-year controlled trial.

METHODS

PATIENTS

Initially, 132 outpatients who satisfied *DSM-III-R* or *DSM-IV* criteria for schizophrenia or schizoaffective disorder and who currently satisfied *Research Diagnostic Criteria for a Selected Group of Functional Disorders*²⁶ were enrolled. (Another 12 referred patients were not enrolled because of mental insufficiency or organicity.) Referrals came from the University of Pittsburgh Medical Center's Comprehensive Care (outpatient) Service, a local mental health center, and a University of Pittsburgh Medical Center satellite clinic following a preliminary population screen of potentially eligible patients. Most patients (76%) were in full or partial remission of positive psychotic symptoms at baseline. For individuals with persistent positive symptoms, stability criteria indicated no serious effect on daily activities. By design, most patients (88%) were more than 1 year past their last hospitalization (median, 46 months) and thus were at reduced risk of relapse.²⁷ Eight of the 132 patients (4 CET recipients and 4 enriched supportive therapy [EST] recipients) withdrew consent before treatment exposure. After assessment, 3 additional patients were judged to be ineligible by reason of mental insufficiency (IQ <80) or organic brain disorder. The final study sample contained 121 patients who met the criteria for cognitive disability, which consisted of the impairments, functional disabilities, and social handicaps associated with 1 of 3 dysfunctional cognitive styles,²⁸ and the criteria for social cognitive disability (Table 1). The styles are continuous rather than categorical: 91% of patients met the criteria for a single style (33% were impoverished, 41% were disorganized, and 17% were rigid) and 9% for multiple styles. These eligibility criteria were assessed during a videotaped, semistructured interview. Patients were fluent in English, aged 18 to 60 years, treated with a Food and Drug Administration–approved antipsychotic medication, and free

Jump to Section

- [Top](#)
- [Introduction](#)
- [Methods](#)
- [Results](#)
- [Comment](#)
- [Author information](#)
- [References](#)

Jump to Section

- [Top](#)
- [Introduction](#)
- [Methods](#)
- [Results](#)
- [Comment](#)
- [Author information](#)
- [References](#)

of serious alcohol or drug abuse in the preceding 6 months, with an IQ of 80 or greater. Final eligibility was determined by team consensus after a review of all diagnostic, historical, and interview materials. [Table 2](#) describes the sample characteristics. Before intake, patients provided a signed informed consent form, and the study was reviewed annually by the University of Pittsburgh institutional review board.

View this table:
[\[in this window\]](#)
[\[in a new window\]](#)

Table 1. Eligibility Criteria

View this table:
[\[in this window\]](#)
[\[in a new window\]](#)

Table 2. Characteristics of 121 Patients With Schizophrenia or Schizoaffective Disorder

DESIGN

Patients were randomized by the project statistician (R.U.) to receive CET or EST and were treated under these conditions for 2 years. To more rapidly form the 11 CET social cognitive groups, 67 patients were randomized to the CET condition and 54 to the EST condition. Ten patients (6 CET recipients and 4 EST recipients) who experienced an interim relapse ($n = 5$) or medical illness ($n = 5$) were given a brief "timeout," were stabilized, and were readmitted to their assigned treatment group. Fourteen patients (12%) terminated treatment early: 8 patients between 4 and 6 months (4 EST recipients and 4 CET recipients) and 6 patients at 12 months (4 EST recipients and 2 CET recipients). Four of these patients became medication refractory (2 EST recipients and 2 CET recipients) and 7 withdrew consent (3 EST recipients and 4 CET recipients); 1 EST patient became alcohol dependent and 2 EST patients died (cancer and heart disease). All 121 patients met the criteria for minimum treatment exposure and were included in the intent-to-treat analyses at 12 months. Before analyzing data, it was deemed inappropriate to carry forward to 24 months the ratings of the 4 CET and 4 EST patients who terminated treatment between 4 and 6 months.

TREATMENTS

Cognitive enhancement therapy theory and practice are described in detail elsewhere.^{5, 28} This therapy was influenced by the holistic program for traumatic brain-injured patients developed by Ben-Yishay and colleagues,²⁹ the integrated cognitive approach of Brenner et al,⁸ and a contemporary theory of human cognitive development.³⁰ Cognitive enhancement therapy attempts to facilitate the attainment of adult social cognitive milestones, such as perspective taking and social context appraisal,³¹⁻³² by shifting an alleged early developmental reliance on effortful, serial, and verbatim (concrete) cognitive processing³³ to a more "gistful," spontaneous abstraction of social themes through structured but unrehearsed in vivo social interactions. Cognitive enhancement therapy is a small-group approach that combines approximately 75 hours of progressive software training exercises in attention, memory, and problem solving with 1.5 hours per week of social cognitive group exercises (approximately 56 sessions). A group (6 patients) began to meet 4 to 6 months after the initiation of attention training. Software exercises required that patients work in pairs, offer mutual support and encouragement, respond to online Socratic coaching, and use the cueing and fading of prompts until the principles underlying test performance were mastered. Three attention training components of Ben-Yishay's Orientation Remediation Module³⁴ were used (the Attention Reaction Conditioner, Zero Accuracy Conditioner and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision making. Attention training was followed by 7 memory routines and ultimately 7 problem-solving exercises from the Bracy PSSCogReHab program³⁵ that represented the Trail Trace, Spatial Memory (sequenced and objects and location), Recall Recognition, Visual/Spatial Memory, Paired Associates and Verbal Memory (categories) exercises. The goal was to develop memory skills through the enhancement of a categorizing capacity, an abstracting attitude, cognitive flexibility, and decision making. Problem-solving exercises included Designer Patterns, Numbers Manipulation I and II, Reversals, Logicmaster, Deduction, and Checker Exchange. These engaging exercises targeted analytic

logic, effortful decision making, strategic and foresightful planning, and the intuitive thinking that supports social cognition.

The group curriculum²⁸ contained activities such as categorization exercises; formation of gistful, condensed messages; solving of real-life social dilemmas; abstraction of themes from the editorial pages of *USA Today*; appraisal of affect and social contexts; initiating and maintaining conversations; play writing; and the center stage exercises Introduce Yourself/Friend adapted from the curriculum of Ben-Yishay.³⁶ Sessions typically contained a homework review, a psychoeducation topic, an exercise by a patient or pair, feedback from other patients and coaches, and a new homework assignment based on the education topic. Although a group contained patients with different cognitive deficits, relative emphasis was placed on the prominent cognitive style deficit of a patient. To provide the best test of CET and EST, most CET patients (74%) were treated by 3 psychologists (S.F., D.G., and A.G.) who, by inclination and training, were disposed toward cognitive interventions. Two master's-level psychiatric nurses (S.C. and A.L.D.), each with 9 years' experience providing personal therapy (PT),³⁷⁻³⁸ on which EST was based, treated most EST patients.

A review of patient performance on each core exercise indicated that all CET patients improved over baseline before proceeding to a new exercise. All patients except 1 with early treatment termination completed the 3 attention exercises, and more than 90% of all memory exercises and problem-solving routines were completed. Excluding 6 early terminators (who accounted for most noncompliance and missing data), the 61 CET recipients who completed 2 years of treatment kept a mean (SD) of 91.3% (4.4%) of their scheduled or rescheduled appointments per therapist. Missed group sessions were reviewed on videotape, and missed computer sessions were rescheduled. Cognitive enhancement therapy was an open, structured, manual-guided intervention that was supervised by 2 CET designers (G.E.H. and S.F.). Computer performance data and adherence to a written group agenda served to ensure fidelity.

Enriched supportive therapy included most practice principles of the basic and intermediate phases of the demonstrably effective PT approach.³⁷⁻³⁸ The intent was to provide a stringent test of CET. Enriched supportive therapy encouraged illness self-management through the control of subjective cues of distress that might lead to destabilization or social dysfunctioning. Phase 1 provided psychological and material support, psychoeducation regarding the nature and treatment of schizophrenia, resumption of instrumental tasks, role restructuring, and basic skills training in stress avoidance. Phase 2 included a personalized education concerning vulnerability to stress, adjustment to disability, identification of early signs of decompensation, and stress management strategies. (These EST components were also made available to CET patients through the group curriculum.) Strategies related to social cognition, such as perspective taking, criticism management, and most PT Advanced-Phase techniques, were strictly avoided. Enriched supportive therapy was intended to be applied weekly in phase 1 and biweekly in phase 2. No attempt was made to match EST to CET hours. (Artificially increasing the hours of a control intervention has been shown to have an adverse effect,¹⁷ and hours of psychosocial treatment have most often not been associated with greater effects in large, well-controlled, multisite studies.³⁹⁻⁴¹) A mean (SD) of approximately 90.8% (6.1%) of scheduled or rescheduled sessions per therapist were kept by the 46 EST patients who completed 2 years of treatment. Enriched supportive therapy was a manual-directed, office-based intervention supervised by a codesigner of the PT approach. Random audiotaped sessions were scale rated for fidelity during the initial years of study. Cost considerations and the absence of therapist drift led to discontinuation of monitoring in the final year of grant support.

MEDICATION

All patients were administered a Food and Drug Administration–approved antipsychotic medication. Medication was not controlled, and compliance was high among all patients, as intended. At baseline, 33.5% of patients received clozapine, 28.9% received an atypical antipsychotic medication (mostly risperidone or olanzapine), and 35.5% received a conventional neuroleptic, typically at the minimum effective dose. By 2 years, these percentages had changed to 41.6%, 33.6%, and 24.8%, respectively. Analyses of medications at baseline and at 1 and 2 years revealed no treatment group differences in either the type or dose of medication or in compliance. Thus, the differential psychosocial treatment effects reported herein cannot be attributed to medication differences. Medication was prescribed by an

experienced research psychiatrist (H.P.).

ASSESSMENTS

Partially correlated behavioral assessments of social cognition, cognitive style, symptoms, and adjustment were selected (or developed) before the study that reflected the observations of clinicians, patients, and family members. Neuropsychological tests of attention, memory, and problem solving were chosen that had historically indicated schizophrenia cognitive impairment.⁴²⁻⁴³ Neuropsychological testing was administered under highly standardized conditions by a psychometrician (R.Z.), who was uninvolved with treatment, and served as a more objective, longitudinal outcome measure on which patients had not been trained.

Before analysis, highly reliable, multivariately derived indices of psychosocial behavior and cognitive functioning were constructed. These "composites" provided protection against the potential error contained in extensive univariate testing that could not be realistically accommodated with Bonferroni corrections. Within each domain, we first selected measures that at face value represented hypothesized outcomes. Following suggestions for constructing summary scores⁴⁴ and approaches that would increase power by reducing within-group variance,⁴⁵ stringent reliability criteria were applied. Candidate variables for a composite had to satisfy test-retest reliability criteria of 0.40 or greater, using the time series panel method across baseline and 1 and 2 years⁴⁶; mean interitem correlations within a composite of 0.30 or greater; mean item-total score correlations of 0.50 or greater (with no item <0.30), and an $\alpha \geq .80$ for the composite itself. Table 3 describes the composites and their reliabilities. The (Bracy) version of the Continuous Performance Test⁵⁹ used by us and the measure of Gist Extraction Deficits failed retest reliability. Also, the Brief Psychiatric Rating Scale Thought Disorder factor, the Major Role Adjustment Inventory Relationships in the Home and Sexual Relationships measures also failed retest reliability because of low variance. Although they satisfied retest reliability criteria, all family measures and most patient measures showed inadequate internal consistency within the assigned composite (or any other composite). Similarly, the Benton Verbal Fluency Test⁶⁰ was insufficiently correlated with other neurocognitive measures and was also excluded.

View this table:
[\[in this window\]](#)
[\[in a new window\]](#)

Table 3. Composite Components and Reliability Values

NEW MEASURES

During pilot studies (36 patients and 6 raters), ongoing revisions of new instruments were made until interrater reliability coefficients were 0.77 or greater, with insignificant rater F ratios. The Cognitive Styles Eligibility Criteria (Table 1) were derived from studies⁶¹⁻⁶³ of acute schizophrenia symptoms reflecting impoverishment (negative symptoms), disorganization, and reality distortion. (During remission, the latter construct seemed to represent a type of rigid, inflexible cognition.²⁸) These styles reflected the cognitive processes with which patients approached instrumental and relationship tasks. Selected NP and neurobiological data support the validity of the constructs.^{61-62,64-66} The styles serve to reduce the heterogeneity in schizophrenia diagnosis⁶² and, we believed, the diverse adaptations to cognitive impairments.²⁸ Clinician retest reliability coefficients were 0.78, 0.64, and 0.69 for the 3 styles, with high independence of styles (intercorrelations ≤ 0.10). The associated Cognitive Styles Inventory was a 46-item micromasure of the 3 styles, which were also well discriminated.

Social cognition was a more difficult concept to measure, with more than 100 definitions available.⁶⁷ We abandoned selected "proxy" measures, previously developed on low-functioning, hospitalized patients (eg, the Social Cue Recognition Test⁶⁸), that showed a ceiling effect among our stable outpatients. We attempted to distinguish social cognition (awareness of relationship aspects) from social adjustment (instrumental role performance or capacity). We relied on the Social Cognition Profile, a 50-item checklist of relevant behaviors gleaned from the literature, for example, Selman and Schultz.⁶⁹ A principal components analysis of the item correlations across rating periods (using >1500 ratings from patients,

families, and clinicians) yielded 4 factors with loadings greater than 0.40 and few split-loaded items. Although the factor structure was nearly identical across different observers (specific variance), when scored, the patient and family factors were highly redundant (common variance). However, the clinician factors were well discriminated. The Social Cognitive Deficit Eligibility Criteria (Table 1) represented our judgment of functionally incapacitating deficits. Because few patients worked full time, we scaled the 4 criterion areas (50 items) used by the Social Security Administration⁵⁸ for determining employment disability (see Social Adjustment in Table 5). Component areas met high interrater (>0.77), retest (>0.62), and internal consistency (>0.87) criteria. Information on these scales is available from one of us (G.E.H.). The results provided herein represent initial validity data.

View this table:
[\[in this window\]](#)
[\[in a new window\]](#)

Table 5. ANCOVA Results at 24 Months on Composite Component-Adjusted Posttreatment Means*

As expected, selected behavioral composites were moderately correlated across periods (Cognitive Style and Symptoms, $r = 0.25$; Social Adjustment and Social Cognition, $r = 0.50$; and Cognitive Style and Social Cognition, $r = 0.44$), indicating some redundancy but nevertheless unique variance. The Neurocognition and Processing Speed composites were only modestly correlated at baseline ($r = 0.30$). Each composite correlated higher with itself across periods than with any other composite.

STATISTICAL ANALYSIS

Composite scores were standardized according to a baseline mean (SD) of 50 (10). The regressed composite change scores between baseline and 1 and 2 years were tested using 2-tailed ($P < .05$) analysis of covariance (ANCOVA) and confirmed by a linear trend analysis of treatment differences across 2 years. In addition to treatment and sex, length of illness (≤ 15 vs > 15 years), baseline positive symptoms (less than mild vs greater than mild), and IQ (≤ 98 vs > 98) dichotomized at the mean were entered as (moderator) factors; the baseline mean served as the covariate. Only the simple interactions of a moderator and treatment condition were examined. Univariate (ANCOVA) analyses were undertaken to identify the relative item contributions within the significant composites at 2 years.

At baseline, the CET and EST groups were not different on any of the demographic or historical variables examined or on the ANCOVA composites or composite items except for the following 4 variables: EST assignees were rated on 3 variables as being less withdrawn, being more socially engaged, and having a higher Global Assessment Scale score by clinicians. Recipients of CET had a somewhat higher estimated average IQ than EST patients (99 vs 95) on the combined Wechsler Adult Intelligence Scale (WAIS) subtests.

RESULTS

MULTIVARIATE MAIN EFFECTS

Table 4 describes the treatment effects on the 6 composites at 1 and 2 years. At 12 months, a robust effect of CET is observed on Processing Speed and Neurocognition, with marginal CET effects observed on the behavioral domains of Cognitive Style, Social Cognition, and Social Adjustment. No effect was seen on the Symptoms composite, as expected. By 2 years, all composites reflected significant differential improvement for CET recipients except for Symptoms. (Linear trend analysis of treatment differences across 2 years yielded the same results.) Effects of CET are broadly applicable to patients because there were no significant (moderator) ANCOVA or linear trend interactive effects with treatment.

Jump to Section

- [Top](#)
- [Introduction](#)
- [Methods](#)
- [Results](#)
- [Comment](#)
- [Author information](#)
- [References](#)

View this table:
[\[in this window\]](#)

Table 4. Treatment Effects on Composite Indices at 12 and 24 Months*

[\[in a new window\]](#)

Effects of CET were unrelated to the receipt of an atypical antipsychotic medication. A 6-factor ANCOVA that entered baseline drug type as an additional moderator (clozapine, atypical antipsychotic, or conventional antipsychotic) revealed no treatment interactions. Drug type had a significant main effect on Cognitive Style and Social Adjustment at 2 years, but not in the expected direction.⁷⁰ These effects indicated greater improvement overall among patients receiving the minimum effective dose of a conventional antipsychotic agent.

EFFECT SIZES

Effect sizes can provide a better indication of clinical significance than *P* values.⁴⁴ Figure 1 illustrates treatment effect sizes (Cohen *d*) that are appropriately calculated on the basis of variance associated with the actual regressed change scores tested by ANCOVA⁷¹ rather than baseline variance. (Within and between groups, an effect size >0.40 is significant at the *P* = .05 level, with *n* = 50 per group.)



Effect sizes of cognitive enhancement therapy (CET) and enriched supportive therapy (EST) at 12 and 24 months by composite index.

View larger version (66K):
[\[in this window\]](#)
[\[in a new window\]](#)

By 2 years, effect sizes for CET exceeded 1 SD for all composites except Symptoms. Large effect size differences (>0.50) between treatments favoring CET occur on the Processing Speed (0.92) and Neurocognition (0.63) composites at 1 year and again on all composites at 2 years except Symptoms. Recipients of EST also show clinically meaningful change by 2 years on many composites, particularly Neurocognition (0.94), an unexpected effect for a psychotherapy that was devoid of targeted cognitive strategies. However, Processing Speed was unaffected by EST. As suggested elsewhere,⁷² a psychotherapeutic approach could lower the stress (arousal) that might exacerbate NP deficits.

UNIVARIATE MAIN EFFECTS

The contribution of the 45 component items to significant composite effects at 2 years are presented in Table 5. Various measures of reaction time, except for the embedded stimulus test, show uniform contributions to the Processing Speed effect. Verbal memory improvement accounts for most change in Neurocognition, with some evidence of improved cognitive flexibility and problem solving. The WAIS Digit Symbol (an indicator of psychomotor speed, cognitive flexibility, and vigilance) also contributes. Regarding Cognitive Style, impoverished cognition improves most and rigid thinking improves least, with disorganization showing intermediate improvement. Differential improvement in Social Cognition is uniform across the composite measures except for the Support factor. Few measures of Social Adjustment achieve statistically significant levels of differential improvement, with measures of improved work capacity indicating relatively greater improvement than actual role performance.

UNIVARIATE TREATMENT INTERACTIONS

There were 9 significant interactions with treatment ($P \leq .05$). Among patients who were ill for less than 15 years, CET recipients improved more than EST recipients on measures of social functioning, the WAIS Digit

Symbol Test, and impoverished cognition. Among patients who were ill for more than 15 years, CET recipients improved more than EST patients on simple reaction time. Patients in the CET group with fewer positive symptoms at baseline improved more than less symptomatic EST patients on the Global Assessment Scale, Wisconsin Card Sorting Test % Conceptual Level Response, and Impoverished cognition. Recipients of CET with a higher IQ improved more on Trails B than EST patients with a higher IQ, and CET patients with a lower IQ increased their WAIS Vocabulary score more than EST patients with a lower IQ. There were no significant interactions with sex.

COMMENT

After 2 years of treatment, CET demonstrated significant differential effects on all domains of behavior and cognition tested except residual symptoms, the latter likely speaking to the clinical stability of patients at baseline and the efficacy of PT in symptom management.³⁸ Modest CET effects on the behavioral composites at 1 year possibly reflect minimal exposure to the CET social group curricula. At the moment, it is unclear how the cognitive changes are causally "linked" to changes in behavior.⁷³ Mediator analyses⁷⁴ that should help clarify causal links are planned.

Jump to Section

- [Top](#)
- [Introduction](#)
- [Methods](#)
- [Results](#)
- [Comment](#)
- [Author information](#)
- [References](#)

Processing speed is a primary mediator candidate because improvement was also observed immediately after training, was sustained over time, and was reserved exclusively for CET recipients. This result supports the observations of other researchers.^{10, 15, 75} Verbal memory is another mediator candidate because it improved most in the first year among the neurocognitive measures and is thought to best predict functioning.⁷⁶ Computerized cognitive training may have been necessary for the differentially superior CET effects; however, substantive gains were also made by EST patients on neurocognition and behavior.

Intelligence is important for understanding treatment effects, particularly those involving cognitive deficits, because higher-IQ patients improved more than lower-IQ patients in both treatments on 12 measures. Although many patients with schizophrenia have a "below average" IQ, and some are alleged to experience a decline in IQ after schizophrenia onset, most are thought to remain within the range of "normal" intelligence and often recover intellectual functioning after successful treatment.⁷⁷ Much of the therapeutic pessimism concerning functional recovery in schizophrenia could be attributed to the minority of patients who have concurrent mental insufficiency (IQ <80), organic brain disorder, or persistent positive symptoms. In our experience, most patients with schizophrenia learn from developmentally appropriate experiences, including their "mistakes." Recommendation for a specific psychosocial intervention in schizophrenia can likely be best made in terms of patient characteristics: intelligence, length of illness, and phase of illness.³⁸

There are potential limitations to our results. Most behavioral findings reflect the assessments of "unblinded" clinicians, although equally robust effects occurred on the blinded NP tests. The relative absence of strong effects in blinded psychosocial treatment trials could speak either to the control of a possible clinician bias or to the issue of questionable validity when assessments are decontextualized.⁷⁸ Studies are needed that evaluate the success of blinding psychosocial treatments and that establish the validity of blinded and clinician assessments against independent criteria (eg, NP tests and neuroimaging changes). Replication studies of CET might profitably blind ratings by using structured interview assessments, such as the Social Adjustment Scale II.⁷⁹ Otherwise, relevant and valid measures of social cognition among stable outpatients were not available at the start of the study and had to be constructed. Further development of these and other proxy measures is an important task.

There are clear reservations regarding the use of NP tests as longitudinal outcome measures,⁸⁰⁻⁸¹ a condition for which these tests were not designed. Schizophrenia cognitive deficits seem to be more generalized than focal⁸²⁻⁸³; thus, the specification and sequencing of training is uncertain. Neither is it clear whether a core cognitive deficit has been remediated (or compensated) or whether the improvement only reflects a tangential correlate of the deficit.⁸⁰ Practice effects are also possible, although it is unlikely that NP tests administered on an annual basis are greatly subject to this bias.⁴⁴ Increased comfort and

familiarity with test procedures,⁸⁰ especially computerized tests, could have positively biased CET neurocognitive and processing speed performance given the extensive computer-based training provided. However, the most robust neurocognitive effects (Wechsler Memory Scale and California Verbal Learning Test memory effects and the WAIS Digit Symbol) were not computerized tests. By design, processing speed was a training goal. Otherwise, some researchers might argue for the dismantling of a multidimensional psychosocial treatment in search of the therapeutic component. However, attempts to deconstruct the software exercises and group components of the similarly organized Ben-Yishay program demonstrated that the whole was clearly superior to the component parts.⁸⁴

Although the goal of the study was to improve social and nonsocial cognition, some researchers might cite the relative absence of robust CET effects on traditional "real-world" outcomes. Relapse (or days hospitalized) was not a hypothesized outcome because most patients were many years past their last psychotic episode. Expected^{27, 85} and observed relapses (9 EST and 3 CET patients) were quite low. Patients were older and ill for longer periods than in our previous studies,⁸⁶⁻⁸⁹ and many had found their "niche," desiring an improved quality of life more than a job or return to school. Furthermore, most patients received disability benefits and the associated health insurance. Coupled with a difficult local labor market and the work disincentives of disability programs, many patients feared a loss of benefits if they increased part-time work or secured full-time, minimum-wage employment. (Our program did not provide job finding, training, or placement but relied on the referral of interested patients to the local Office of Vocational Rehabilitation.) Nevertheless, CET gains in adjustment were observed, an encouraging outcome given the stable pretreatment status of patients and the efficacy of EST. The CET trend in employment (Table 5) is attributed to the greater number of CET patients who found volunteer positions (26% of CET and 8% of EST patients) rather than paid employment. The CET gain in Major Role Performance (Table 5) reflects the observation that 60% of CET patients vs 42% of EST patients equaled or exceeded their best premorbid or previous functioning. The 3-year follow-up should provide a better assessment of adjustment effects.

Finally, CET results cannot be generalized to all patients with schizophrenia. It was designed as a recovery-phase intervention for stable, non-substance-abusing ambulatory patients with an IQ of 80 or higher. Behavioral, compensatory approaches¹⁷ might be preferable for the more severely impaired or intellectually compromised subpopulations of patients. Cognitive behavior therapy, PT, skills training, and family psychoeducation seem to be more appropriate for those in the subacute, stabilization phase.³⁸ Although we lack data for a cost-benefit analysis, programs that rely on small-group rehabilitation approaches should find that CET is cost-effective. Most patients (87%) highly endorsed their CET experience. The stable patient with rehabilitation potential is more likely to functionally improve after extended cognitive rehabilitation. In the era of managed cost, even expert consensus opinion⁹⁰ tends to disenfranchise this substantial segment of the schizophrenia population.

In conclusion, the cognitive disabilities of schizophrenia do not need to be the persistent deficits described in numerous naturalistic, longitudinal studies.⁹¹⁻⁹² Instead, many of these disabilities are capable of improvement after adequate exposure to cognitive rehabilitation.

AUTHOR INFORMATION

Correspondence: Gerard E. Hogarty, MSW, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O'Hara St, Pittsburgh, PA 15213 (hogartyje@upmc.edu).

Submitted for publication January 27, 2003; final revision received March 11, 2004; accepted March 16, 2004.

This study was supported by grant MH-30750 from the National Institute of Mental Health, Bethesda, Md.

We thank the clinicians of the University of Pittsburgh Medical Center's Comprehensive Care Service and Diane Ludewig, PhD, and Prabir Mullick, MD, for patient referrals; David Kupfer, MD, chairperson of the

Jump to Section

- [Top](#)
- [Introduction](#)
- [Methods](#)
- [Results](#)
- [Comment](#)
- [Author information](#)
- [References](#)

University of Pittsburgh Medical Center Department of Psychiatry, and Robert Prien, PhD, formerly of the National Institute of Mental Health, Bethesda, for extended support and encouragement at critical times; Sander Kornblith, PhD, for providing direction and treatment fidelity for EST; Odie Bracy, PhD, for graciously providing his memory and problem-solving exercises; Yehuda Ben-Yishay, PhD, for offering his attention training software and opening his program to multiple visits by CET therapists before the study; Michele Bauer for preparing grant applications and the manuscript and for overseeing administrative details; and the study patients for being dedicated to their recovery (which was a constant source of inspiration and encouragement).

From the University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, Pa. Dr Flesher is now with Planned Life Assistance Network (PLAN) of Northeast Ohio, Cleveland Heights.

REFERENCES

1. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. *Lancet*. 1997;349:1436-1442. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
2. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? *Schizophr Bull*. 2000;26:119-136. [ISI](#) | [PUBMED](#)
3. Taylor EH, Cadet JL. Social intelligence: a neurological system? *Psychol Rep*. 1989;64:423-444. [ISI](#) | [PUBMED](#)
4. Pinkham AE, Penn DL, Perkins DO, Lieberman J. Implications for the neural basis of social cognition for the study of schizophrenia. *Am J Psychiatry*. 2003;160:815-824. [FREE FULL TEXT](#)
5. Hogarty GE, Flesher S. A developmental theory for a Cognitive Enhancement Therapy of schizophrenia. *Schizophr Bull*. 1999;25:677-692. [ISI](#) | [PUBMED](#)
6. Silverstein SM. Information processing, social cognition, and psychiatric rehabilitation in schizophrenia. *Psychiatry*. 1997;60:327-340. [ISI](#) | [PUBMED](#)
7. Olbrick R, Mussgay L. Reduction of schizophrenic deficits by cognitive training: an evaluative study. *Eur Arch Psychiatry Neurol Sci*. 1990;239:366-369. [PUBMED](#)
8. Brenner HD, Hodel B, Roder V, Corrigan P. Treatment of cognitive dysfunctions and behavior deficits in schizophrenia. *Schizophr Bull*. 1992;18:21-26. [ISI](#) | [PUBMED](#)
9. Jaeger J, Douglas E. Neuropsychiatric rehabilitation for persistent mental illness. *Psychiatr Q*. 1992;63:71-94. [PUBMED](#)
10. Medalia A, Aluma M, Tryon W, Merriam A. Effectiveness of attention training in schizophrenia. *Schizophr Bull*. 1998;24:147-152. [ISI](#) | [PUBMED](#)
11. Wykes T, Dunn G. Cognitive deficit and the prediction of rehabilitation success in a chronic psychiatric group. *Psychol Med*. 1992;22:389-398. [ISI](#) | [PUBMED](#)
12. Wykes T, Reeder C, Corner J, Williams C, Everett B. The effects of neurocognitive remediation on executive processing in patients with schizophrenia. *Schizophr Bull*. 1999;25:657-676. [ISI](#) | [PUBMED](#)
13. Spaulding W, Reed D, Sullivan M, Richardson C, Weiler M. Effects of cognitive treatment in psychiatric rehabilitation. *Schizophr Bull*. 1999;25:657-676. [ISI](#) | [PUBMED](#)
14. Medalia A, Revheim H, Casey M. The remediation of problem-solving skills in schizophrenia. *Schizophr Bull*. 2001;27:259-267. [ISI](#) | [PUBMED](#)
15. Silverstein SM, Menditto AA, Stuve P. Shaping attention span: an operant conditioning procedure to improve neurocognition and functioning in schizophrenia. *Schizophr Bull*. 2001;27:247-257. [ISI](#) | [PUBMED](#)
16. Bell M, Bryson G, Greig T, Corcoran C, Wexler BE. Neurocognitive enhancement therapy with work therapy: effects on neuropsychological test performance. *Arch Gen Psychiatry*. 2001;58:763-768. [FREE FULL TEXT](#)
17. Velligan DI, Bow-Thomas LC, Huntzinger C, Ritch J, Ledbetter N, Prihoda TJ, Miller AL. Randomized controlled trial of the use of compensating strategies to enhance adaptive functioning in outpatients with schizophrenia. *Am J Psychiatry*. 2000;157:1317-1323. [FREE FULL TEXT](#)
18. van der Gaag M, Kern RS, van den Bosch RJ, Liberman RP. A controlled trial of cognitive remediation in schizophrenia. *Schizophr Bull*. 2002;28:167-176. [ISI](#) | [PUBMED](#)
19. Benedict RHB, Harris AE, Markow T, McCormick JA, Nuechterlein KH, Asarnow RF. Effects of attention

Jump to Section

- [Top](#)
- [Introduction](#)
- [Methods](#)
- [Results](#)
- [Comment](#)
- [Author information](#)
- [References](#)

- training on information processing in schizophrenia. *Schizophr Bull.* 1994;20:537-546. [ISI](#) | [PUBMED](#)
20. Kern RS, Wallace CJ, Hellman SG, Womack LM, Green MF. A training procedure for remediating WCST deficits in chronic psychotic patients: an adaptation of errorless learning principles. *J Psychiatr Res.* 1996;30:283-294. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
21. Wexler BE, Hawkins KA, Rounsaville B, Anderson M, Sernyak MJ, Green MF. Normal neurocognitive performance after extended practice in patients with schizophrenia. *Schizophr Res.* 1997;26:173-180. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
22. Spaulding WD, Fleming SK, Reed D, Sullivan M, Storzbach D, Lam M. Cognitive functioning in schizophrenia: implications for psychiatric rehabilitation. *Schizophr Bull.* 1999;25:275-289. [ISI](#) | [PUBMED](#)
23. O'Carroll RE, Russell HH, Lawerence SM, Johnstone EC. Errorless learning and the cognitive rehabilitation of memory impaired schizophrenic patients. *Psychol Med.* 1999;29:105-112. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
24. Keshavan MS, Hogarty GE. Brain maturational processes and delayed onset in schizophrenia. *Dev Psychopathol.* 1999;11:525-543. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
25. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. *Am J Psychiatry.* 2003;160:1209-1222. [FREE FULL TEXT](#)
26. Spitzer RL, Endicott J, Robins E. *Research Diagnostic Criteria (RDC) for a Select Group of Functional Disorders.* 3rd ed. New York: New York State Psychiatric Institute; 1978.
27. Hogarty GE, Ulrich RF. Temporal effects of drug and placebo in delaying the relapse of schizophrenic patients. *Arch Gen Psychiatry.* 1977;34:297-301. [ABSTRACT](#)
28. Hogarty GE, Flesher S. Practice principles of Cognitive Enhancement Therapy. *Schizophr Bull.* 1999;25:693-708. [ISI](#) | [PUBMED](#)
29. Ben-Yishay Y, Rattok J, Lakin P, Piasetsky E, Ross B, Silver S, Zide E, Ezrachi O. Neuropsychological rehabilitation: quest for a holistic approach. *Semin Neurol.* 1985;5:252-259. [ISI](#)
30. Brainerd CJ, Reyna VF. Gist is the grist: fuzzy trace theory and the new intuitionism. *Dev Rev.* 1990;10:3-47. [ISI](#)
31. Berger P, Luckman T. *The Social Construction of Reality.* Garden City, NJ: Doubleday; 1966.
32. Brim OG. Socialization through the life cycle. In: Brim OG, Wheeler S, eds. *Socialization After Childhood.* New York, NY: John Wiley & Sons Inc; 1966:3-49.
33. Strandburg RJ, Marsh JT, Brown WS, Asarnow RF, Gultrie D. Information processing deficits across childhood- and adult-onset schizophrenia. *Schizophr Bull.* 1994;20:685-695. [ISI](#) | [PUBMED](#)
34. Ben-Yishay Y, Piasetsky EB, Rattok J. A systematic method for ameliorating disorders in basic attention. In: Meir MJ, Benton AL, Diller L, eds. *Neuropsychological Rehabilitation.* New York, NY: Guilford Press; 1985:165-181.
35. Psychological Software Services Inc. PSSCogReHab program. Available at: <http://www.neuroscience.cnter.com/>.
36. Ben-Yishay Y. *Working Approaches to Remediation of Cognitive Deficits in Brain Damaged Persons: Rehabilitation Monograph No.61.* New York, NY: New York University Medical Center; 1980.
37. Hogarty GE, Greenwald D, Ulrich RF, Kornblith SJ, DiBarry AL, Cooley S, Carter M, Flesher S. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, II: effects on adjustment of patients. *Am J Psychiatry.* 1997;154:1514-1524. [FREE FULL TEXT](#)
38. Hogarty GE. *Personal Therapy for Schizophrenia and Related Disorders: A Guide to Individualized Treatment.* New York, NY: Guilford Press; 2002.
39. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF. Drug and sociotherapy in the aftercare of schizophrenic patients, II: two-year relapse rates. *Arch Gen Psychiatry.* 1974;31:603-608. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
40. Gunderson JG, Frank AF, Katz HM, Vannicelli ML, Frisch JP, Knapp PH. Effects of psychotherapy in schizophrenia, II: comparative outcome of two forms of treatment. *Schizophr Bull.* 1984;10:564-598. [ISI](#) | [PUBMED](#)
41. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick IS, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. *Arch Gen Psychiatry.* 1997;54:453-463. [ABSTRACT](#)
42. Heaton RK, Baade LE, Johnson KL. Neuropsychological results associated with psychiatric disorders. *Psychol Bull.* 1978;85:141-162. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)

43. Straube ER, Oades RD. *Schizophrenia: Empirical Research and Findings*. San Diego, Calif: Academic Press; 1992.
44. Kraemer HC. Psychometrics and qualities of cognitive tests for clinical trials. Paper presented at: NIMH Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Meeting; April 14, 2003; Potomac, Md.
45. Kraemer HC. To increase power in randomized clinical trials without increasing sample size. *Psychopharmacol Bull*. 1991;27:217-225. [ISI](#) | [PUBMED](#)
46. Hannan MT, Young SS. Estimation in panel models: results on pooling cross-sections and time series. *Sociol Methodol*. 1977;8:52-83.
47. Wechsler D. *Manual for the Wechsler Memory Scale-Revised*. San Antonio, Tex: Psychological Corp; 1987.
48. Delis DC, Kramer JH, Kaplan E, Ober BA. *California Verbal Learning Test (CVLT) Manual*. San Antonio, Calif: Psychological Corp; 1987.
49. Wechsler D. *Wechsler Adult Intelligence Scale-Revised*. New York, NY: Psychological Corp; 1981.
50. Reitan RM, Waltson D. *The Halstead-Reitan Neuropsychological Test Battery*. Tucson, Ariz: Neuropsychology Press; 1985.
51. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. *Wisconsin Card Sorting Test Manual: Revised and Expanded*. Odessa, Fla: Psychological Assessment Resources Inc; 1993.
52. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychol Rep*. 1962;10:799-812. [ISI](#)
53. Wing JK. A simple and reliable subclassification of chronic schizophrenia. *J Ment Sci*. 1961;107:862-875. [ISI](#) | [PUBMED](#)
54. Raskin A, Schulterbrant J, Reatig N, McKean JJ. Replication of factors of psychopathology in interview, ward behavior, and self-report ratings of hospitalized depressives. *J Nerv Ment Dis*. 1969;148:87-98. [ISI](#) | [PUBMED](#)
55. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J. Pharmacotherapy of impaired affect in recovering schizophrenic patients. *Arch Gen Psychiatry*. 1995;52:29-41. [ABSTRACT](#)
56. Hogarty GE, Goldberg SC, Schooler NR. Drug and sociotherapy in the aftercare of schizophrenic patients, III: adjustment of nonrelapsed patients. *Arch Gen Psychiatry*. 1974;31:609-618. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
57. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. *Arch Gen Psychiatry*. 1976;33:766-771. [ABSTRACT](#)
58. Mental disorders—adult. In: US Department of Health and Human Services. *Disability Evaluation Under Social Security*. Washington, DC: US Dept of Health and Human Services; 1986:61-68. SSA Publication No. 64-039.
59. Rosvold HE, Mirsky AF, Sarason I, Bransome ED, Beck LH. A continuous performance test of brain damage. *J Consult Psychiatry*. 1956;20:343-350.
60. Benton AL, Hamsher K. *Multilingual Aphasia Examination*. Iowa City: University of Iowa Press; 1976.
61. Liddle PF. Schizophrenic syndromes, cognitive performance, and neurological dysfunction. *Psychol Med*. 1987;17:49-57. [ISI](#) | [PUBMED](#)
62. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. *J Nerv Ment Dis*. 1994;182:193-203. [ISI](#) | [PUBMED](#)
63. Andreason NC, Arndt S, Alliger R, Miller D, Flaum M. Symptoms of schizophrenia. *Arch Gen Psychiatry*. 1995;52:341-351. [ABSTRACT](#)
64. Liddle PF, Morris DC. Schizophrenia syndromes, frontal lobe performance and neurological dysfunction. *Br J Psychiatry*. 1991;158:340-348. [ABSTRACT](#)
65. Brown KW, White T. Syndromes of chronic schizophrenia and some clinical correlates. *Br J Psychiatry*. 1992;161:317-322. [ABSTRACT](#)
66. Norman RMG, Malla AK, Morrison-Stewart SL, Hilmes E, Williamson PC, Thomas J, Cortese L. Neuropsychological correlates of syndromes in schizophrenia. *Br J Psychiatry*. 1997;170:134-139. [ABSTRACT](#)
67. Wyer RS, ed, Srull TK, ed. *Handbook of Social Cognition*. Hillsdale, NJ: Lawrence Erlbaum Associates Publishers; 1994. *Basic Processes*; vol I.
68. Corrigan PW, Green MF. Schizophrenic patients' sensitivity to social cues: the role of abstraction. *Am J Psychiatry*. 1993;150:589-594. [ABSTRACT](#)

69. Selman RL, Schultz LH. *Making a Friend in Youth*. Chicago, Ill: University of Chicago Press; 1990.
70. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. *Schizophr Bull*. 1999;25:201-222. [ISI](#) | [PUBMED](#)
71. The analyses of variance and covariance. In: Cohen J. *Statistical Power Analyses for the Behavioral Sciences*. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates Publishers; 1988:379.
72. Spaulding WD, Storms L, Goodrich V, Sullivan M. Applications of experimental psychopathology in psychiatric rehabilitation. *Schizophr Bull*. 1986;12:560-577. [ISI](#) | [PUBMED](#)
73. Green MF, Neurchterlein KH. Should schizophrenia be treated as a neurocognitive disorder? *Schizophr Bull*. 1999;25:309-319. [ISI](#) | [PUBMED](#)
74. Kraemer HC, Wilson GT, Fairburn CG, Agros WS. Mediators and moderators of treatment effects in randomized clinical trials. *Arch Gen Psychiatry*. 2002;59:877-883. [FREE FULL TEXT](#)
75. Wykes T, Stuart E, Katz R. The prediction of rehabilitative success after three years: the use of social, symptom and cognitive measures. *Br J Psychiatry*. 1990;157:865-870. [ABSTRACT](#)
76. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry*. 1996;153:321-330. [ABSTRACT](#)
77. Aylward E, Walker E, Bettes B. Intelligence in schizophrenia: meta-analysis of the research. *Schizophr Bull*. 1984;10:430-459. [ISI](#) | [PUBMED](#)
78. Cohen CI. Overcoming social amnesia: the role for a social perspective in psychiatric research and practice. *Psychiatr Serv*. 2000;51:72-78. [FREE FULL TEXT](#)
79. Schooler N, Hogarty GE, Weissman MM. Social Adjustment Scale II. In: Hargraves WA, Atkinson CC, Sorenson JE, eds. *Resource Materials for Community Mental Health Program Evaluations*. Washington, DC: US Government Printing Office; 1979:290-303. DHEW Publication 79-328.
80. Bellack AS, Gold JM, Buchanan RW. Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. *Schizophr Bull*. 1999;25:257-274. [ISI](#) | [PUBMED](#)
81. Levy DL. Location, location, location: the pathway from behavior to brain locus in schizophrenia. In: Matthysse S, Levy DL, Kagan J, Benes FM, eds. *Psychopathology: The Evolving Science of Mental Disorder*. New York, NY: Cambridge University Press; 1996:101-126.
82. Blanchard JJ, Neale JM. The neuropsychological signature of schizophrenia: generalized or differential deficit? *Am J Psychiatry*. 1994;151:40-48. [ABSTRACT](#)
83. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia. *Arch Gen Psychiatry*. 1999;56:749-752. [FREE FULL TEXT](#)
84. Rattok J, Ben-Yishay Y, Lakin P, Piasetsky E, Ross B, Silver S, Vakil E, Zide E, Diller L. Outcome of differential mixes in a multidimensional neuropsychological rehabilitation program. *Neuropsychology*. 1991;6:395-415. [FULL TEXT](#)
85. Johnson DAW, Pasterski G, Ludlow JM, Street T, Taylor RDW. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients. *Acta Psychiatr Scand*. 1983;67:339-352. [ISI](#) | [PUBMED](#)
86. Hogarty GE, Goldberg SC, Collaborative Study Group. Drug and sociotherapy in the aftercare of schizophrenic patients: one-year relapse rates. *Arch Gen Psychiatry*. 1973;28:54-64. [FULL TEXT](#) | [ISI](#) | [PUBMED](#)
87. Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, Madonia MJ. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia, I: one-year effects of a controlled study on relapse and expressed emotion. *Arch Gen Psychiatry*. 1986;43:633-642. [ABSTRACT](#)
88. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, Cooley SJ, Ulrich RF, Carter M, Madonia MJ. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results of a two-year controlled study. *Arch Gen Psychiatry*. 1988;45:797-805. [ABSTRACT](#)
89. Hogarty GE, Kornblith SF, Greenwald D, DiBarry AL, Cooley S, Ulrich R, Carter M, Flesher S. Three-year trials of personal therapy among schizophrenic patients living with or independent of family, I: description of study and effects on relapse rates. *Am J Psychiatry*. 1997;154:1504-1513. [FREE FULL TEXT](#)
90. McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guidelines Series: treatment of schizophrenia. *J Clin Psychiatry*. 1999;60(suppl 11):1-80.
91. Rund BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. *Schizophr Bull*. 1998;24:425-435. [ISI](#) | [PUBMED](#)
92. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TP, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. *Arch Gen Psychiatry*. 2001;58:24-32. [FREE FULL TEXT](#)

RELATED ARTICLE

This Month in *Archives of General Psychiatry*

Arch Gen Psychiatry. 2004;61:863.

[FULL TEXT](#)

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cognitive Rehabilitation for Schizophrenia and the Putative Role of Motivation and Expectancies

Velligan et al.

Schizophr Bull 2006;32:474-485.

[ABSTRACT](#) | [FULL TEXT](#)

Social Perception as a Mediator of the Influence of Early Visual Processing on Functional Status in Schizophrenia

Sergi et al.

Am. J. Psychiatry 2006;163:448-454.

[ABSTRACT](#) | [FULL TEXT](#)

Understanding the Glass Ceiling for Functional Outcome in Schizophrenia

CARTER

Am. J. Psychiatry 2006;163:356-358.

[FULL TEXT](#)

A Collaborative Approach to Targeted Treatment Development for Schizophrenia: A Qualitative Evaluation of the NIMH-MATRICES Project

Bromley

Schizophr Bull 2005;31:954-961.

[ABSTRACT](#) | [FULL TEXT](#)

What Predicts a Good Response to Cognitive Remediation Interventions?

Medalia and Richardson

Schizophr Bull 2005;31:942-953.

[ABSTRACT](#) | [FULL TEXT](#)

Cognitive Remediation and Vocational Rehabilitation for Schizophrenia

Wexler and Bell

Schizophr Bull 2005;31:931-941.

[ABSTRACT](#) | [FULL TEXT](#)

Cognitive Training and Supported Employment for Persons With Severe Mental Illness: One-Year Results From a Randomized Controlled Trial

McGurk et al.

Schizophr Bull 2005;31:898-909.

[ABSTRACT](#) | [FULL TEXT](#)

Reinventing Evidence-Based Interventions?

Hogarty

PS 2005;56:1156-1156.

[FULL TEXT](#)

Sustained Remission of Schizophrenia

LIBERMAN and KOPELOWICZ

Am. J. Psychiatry 2005;162:1763-1763.

[FULL TEXT](#)

Recovery From Schizophrenia: A Concept in Search of Research

Lieberman and Kopelowicz

PS 2005;56:735-742.

[FULL TEXT](#)

Therapy Program Improves Cognition in Patients

Arehart-Treichel

Psychiatr News 2004;39:22-23.

[FULL TEXT](#)

Psychotherapy Enhances Cognitive Function in Schizophrenia

Journal Watch Psychiatry 2004;2004:7-7.

[FULL TEXT](#)

[HOME](#) | [CURRENT ISSUE](#) | [PAST ISSUES](#) | [COLLECTIONS](#) | [CAREERNET](#) | [CONTACT US](#) | [HELP](#)
[CONDITIONS OF USE](#) | [PRIVACY POLICY](#)

© 2004 American Medical Association. All Rights Reserved.